John J. Miller, MD

Explore how dopamine D2 blockade shapes antipsychotic benefits and risks, revealing dosing pitfalls, polypharmacy harms, and why plasma level monitoring improves outcomes.

A panel of expert psychiatrists define deprescribing as ongoing medication review, guiding safer, personalized psychopharmacology amid polypharmacy, misdiagnosis, and fragmented care.

In the first ever episode of "On Your Mind With Erin Crown," explore how tribalism hurts the field of psychiatry and ultimately patient outcomes.

Why psychiatry’s growing “tribalism” harms care—and how clinicians, academia, and pharma can unite to tackle untreated mental illness.

Learn how CYP450 genetics, phase 2 metabolism, and drug interactions shape psychiatric dosing—what’s actionable now and what’s next in PPGx.

Explore the brain’s 5 monoamines—beyond serotonin and dopamine—revealing histamine, melatonin, and trace amines shaping sleep, appetite, and mood.

Review the origins and advancements of ECT.

ASCP awardee Leslie Citrome explains why effect size, NNT, and NNH beat P-values, helping clinicians choose treatments tailored to each patient.

Clinicians explore transdiagnostic anhedonia—reward learning, loneliness, and digital rewards—offering practical ideas to personalize treatment.

Investigational depression drugs target SIRT6 epigenetics, histamine H3, and AMPA.

The ASCp meeting spotlights a fast-acting psychedelic for postpartum depression, vasopressin-targeting drugs, and ketamine’s promise for Parkinson symptoms.

ASCP 2026 leaders share practical ways to engage patients in acute psychosis—active listening, noncollusive language, and rapport before assessment.

John J. Miller, MD, Psychiatric Times editor in chief, looks forward to learning and sharing the late-breaking science, expert interviews, and new podcast conversations in psychopharmacology.

Psychiatry leaders unpack pharmacogenetic testing hype, spotlight 4 actionable genes, and urge evidence-based use with therapeutic drug monitoring for personalized treatment.

Learn how genetics shape psych med response and dosing.

New psychiatry drugs target dementia agitation, ADHD, depression, TRD, and schizophrenia—see which novel mechanisms may reach the FDA next.

FDA approves Axsome’s AXS-05 for Alzheimer’s agitation, backed by multiple trials.

Explore how sigma‑1 receptors shape ER–mitochondria signaling, calm neuroinflammation, and inspire therapies from fluvoxamine to dextromethorphan.

Learn more about the history of pharmacogenomics.

Why DSM diagnoses shape treatment and insurance denials—and how a WHO-aligned, dimension-based system could modernize psychiatry beyond DSM-5-TR.

Explore how glutamate and GABA balance brain excitation and inhibition, shaping development, learning, and disorders like depression, schizophrenia, and autism.

APA shares DSM recommendations, and John J. Miller, MD, reviews and weighs in.

How ketamine sparks a glutamate-driven BDNF burst, reshaping prefrontal connectivity in depression and revealing the glutamate–GABA partnership.

John J. Miller, MD, weighs in on APA's plans for the DSM and why global integration with the ICD should shape psychiatry’s future.

In response to the APA’s roadmap for the future DSM, John J. Miller, MD, examines how its rigid diagnostic categories may limit clinicians’ ability to deliver care.

John Miller, MD, discusses the APA's new publications on the future of the DSM, highlighting key domains for mental health diagnosis and treatment.

In this CME article, explore the groundbreaking role of muscarinic cholinergic receptors in schizophrenia treatment, highlighting innovative therapies like KarXT for improved patient outcomes.

Psychiatric Times is excited to embrace change with new digital editions and engaging content, and invite you, our readers, to explore diverse topics across multiple platforms.